Is ARGENX SE (ARGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 7.6% / 30% | 2.0% / 30% | 6.33% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 7.6% / 33% | 2.0% / 33% | 6.33% / 5% | ✗ NOT HALAL |
| MSCI | 0.6% / 33% | 54.5% / 33% | 14.7% / 33% | 6.33% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 7.6% / 33% | 2.0% / 33% | 6.33% / 5% | ✗ NOT HALAL |
| FTSE | 0.6% / 33% | 54.5% / 33% | 14.7% / 50% | 6.33% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 57.2% | |
| Operating Margin | 27.4% | |
| Net Margin | 30.5% | |
| Return on Equity (ROE) | 20.2% | |
| Return on Assets (ROA) | 8.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$83M |
| Free Cash Flow | -$151M |
| Total Debt | $39M |
| Debt-to-Equity | 0.6 |
| Current Ratio | 5.2 |
| Total Assets | $6.2B |
Price & Trading
| Last Close | $692.83 |
| 50-Day MA | $780.84 |
| 200-Day MA | $752.67 |
| Avg Volume | 363K |
| Beta | -0.2 |
|
52-Week Range
$510.06
| |
About ARGENX SE (ARGX)
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ARGENX SE (ARGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ARGENX SE is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ARGENX SE's debt ratio?
ARGENX SE's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.
What are ARGENX SE's key financial metrics?
ARGENX SE has a market capitalization of $42.9B, trailing P/E ratio of 35.3, and revenue of $2.2B. The company maintains a gross margin of 57.2% and a net margin of 30.5%. Return on equity stands at 20.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.